Get started
NEOCORE TECHNOLOGY CO LTDNEOCORE TECHNOLOGY CO LTDNEOCORE TECHNOLOGY CO LTD

NEOCORE TECHNOLOGY CO LTD

33.10TWDR
−0.90−2.65%
At close at Jul 4, 06:31 GMT
TWD
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Seasonals

4131 fundamentals

Key facts

Market capitalization‪1.34 B‬TWD
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−1.15TWD
Founded1998
Employees (FY)—
CEOWen Sheng Ji
Websitebio-drchip.com.tw
About

NeoCore Technology Co., Ltd. engages in the research, development, manufacture, and sale of biochips. It develops and provides food safety examination system, human diagnosis arrays system, agriculture examination system, food examination arrays system and laboratory instruments and design system. The company's products include biochips, fast nucleic acid hybridization devices, nucleic acid extraction kits, and polymerase chain reaction kits. NeoCore Technology was founded on October 22, 1998 and is headquartered in Tainan, Taiwan.

Ownership
‪‪39.50 M‬‬
Free Float shares
‪‪30.24 M‬‬ (76.55%)
Closely held shares
‪‪9.26 M‬‬ (23.45%)
Free Float shares
‪‪30.24 M‬‬ (76.55%)
Closely held shares
‪‪9.26 M‬‬ (23.45%)
Capital structure
Market cap
‪‪1.34 B‬‬
Debt
‪‪167.39 M‬‬
Minority interest
‪‪22.17 M‬‬
Cash & equivalents
‪‪123.77 M‬‬
Enterprise value
‪‪1.41 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪1.34 B‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
11.49x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
11.49x
Valuation ratios
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪6.00‬
‪12.00‬
‪18.00‬
‪24.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−99%‬
‪−78%‬
‪−57%‬
‪−36%‬
‪−15%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−25.00 M‬‬
‪0.00‬
‪‪25.00 M‬‬
‪‪50.00 M‬‬
‪‪75.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−25.00 M‬‬
‪0.00‬
‪‪25.00 M‬‬
‪‪50.00 M‬‬
‪‪75.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−25.00 M‬‬
‪0.00‬
‪‪25.00 M‬‬
‪‪50.00 M‬‬
‪‪75.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Contact Lenses
Biotechnology
By country
Period: 2024
Taiwan

Dividends

Dividend yield, history and sustainability

No dividends
4131 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−90.00 M‬‬
‪0.00‬
‪‪90.00 M‬‬
‪‪180.00 M‬‬
‪‪270.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪80.00 M‬‬
‪‪160.00 M‬‬
‪‪240.00 M‬‬
‪‪320.00 M‬‬
Assets
Liabilities